Multivariate analysis for relapse in patients without any acute or chronic GVHD who underwent a URD or HLA-identical sibling transplantation for AML, ALL, and CML
| Factors . | Relative risk . | 95% CI . | P . |
|---|---|---|---|
| AML*: URD vs sib | 1.33 | 0.90-1.97 | .16 |
| ALL†: URD vs sib | 0.61 | 0.30-1.28 | .19 |
| CML‡: URD vs sib | 0.82 | 0.45-1.52 | .53 |
| Factors . | Relative risk . | 95% CI . | P . |
|---|---|---|---|
| AML*: URD vs sib | 1.33 | 0.90-1.97 | .16 |
| ALL†: URD vs sib | 0.61 | 0.30-1.28 | .19 |
| CML‡: URD vs sib | 0.82 | 0.45-1.52 | .53 |
In patients without acute and chronic GVHD, relapse is similar for AML, ALL, and CML between URD and HLA-identical sibling transplations. RR for reference group (sib) is 1.0.
URD indicates unrelated donor; sib, HLA-identical sibling; AML, acute myeloid leukemia; ALL, acute lymphoid leukemia; CML, chronic myeloid leukemia, GVHD, graft-versus-host disease; CI, confidence interval; WBC, white blood cell; and CR1, first complete remission.
Model adjusted for duration of CR1 and cytogenetics, and stratified by disease stage, Karnofsky score, and graft type.
Model also adjusted for WBC count at diagnosis and stratified by disease stage, Karnofsky score, and graft type.
Model also adjusted for disease stage and stratified by Karnofsky score and graft type.